At Healx, we believe every rare disease patient deserves a treatment. Our Senior Director, Drug Discovery Richard Davenport FRSC and Head of Operations, People & Tech Nick Street will be participating in the OBN (UK) Ltd Ltd BioTuesday session next week in London. They will contribute to a conversation about the funding landscape and regulatory challenges within the #raredisease space and hear first-hand from a rare disease patient group. Read more about the event here: https://lnkd.in/gbv-ahjK
Healx
Biotechnology Research
Cambridge, Cambridgeshire 18,005 followers
AI-powered and patient-inspired. We accelerate the discovery and development of rare disease treatments.
About us
Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
- Website
-
http://www.healx.ai
External link for Healx
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Cambridgeshire
- Type
- Privately Held
- Founded
- 2014
Locations
-
Primary
Get directions
66-68 Hills Rd
Charter House
Cambridge, Cambridgeshire CB21LA, GB
Employees at Healx
Updates
-
Growth is a journey fueled by curiosity, collaboration, and mutual respect for one another. Our team is dedicated to learning, sharing knowledge, and amplifying every voice to drive meaningful impact for the #raredisease community. By embracing diverse perspectives and fostering an environment of trust, we empower one another to continuously evolve and excel, leading to better outcomes. Learn more about our company values here: https://healx.ai/about/
-
Exciting Progress in Rare Disease Treatment at Healx! Proud to share that our lead program, HLX-1502, has received FastTrack designation from the FDA, bringing us one step closer to delivering a breakthrough treatment for neurofibromatosis type 1 (NF1). This designation underscores the urgent need for new therapeutic options in NF1 and accelerates our path to making a real impact for patients and their families. Explore our latest blog to learn more about HLX-1502, what FastTrack means for our team and the NF1 community, and the next steps in our journey. Read more on our website: https://lnkd.in/gjMayGgP #Healx #RareDisease #NF1 #FastTrack #Biotech #FDA
-
In a recent Forbes article, our CEO, Tim Guilliams, shared insights on the challenges founders face and the importance of resilience. Building a company, especially one like Healx focused on #rarediseases, requires both innovation and personal wellbeing. At Healx, we recognise that founder health is crucial to sustained success. Supporting a culture that values mental and physical resilience benefits not only each individual at our company but our entire mission. Read the full article here: https://lnkd.in/gESqgxty
"Balderton's Founder Wellbeing and Performance platform was life changing for me, especially the WellFounded programme. It helped me figure out my ‘personal resilience manual’. Before joining the programme, I was operating at 20-25% energy, I was effectively burned out. Like many founders, I used to ‘fly, crash, fly, crash’ but WellFounded gave me the gift of personal resilience. Since completing the programme, I’ve consistently maintained a 85% energy and mood, day in day out without crashing. Worth absolute gold." Tim Guilliams, co-founder and CEO of Healx. Thank you, Tim, for sharing your story, and to Trevor Clawson at Forbes for such a thoughtful write-up of today's news and the benefits that can be had when founders are given the tools and permission to take care of their wellbeing and performance. Read the full article at the link in the comments.
-
-
We recently hosted our quarterly team days in Cambridge, UK! Team days are a great opportunity for the full Healx team to get together and connect on our mission to transform the lives of individuals living with #rarediseases. During three action-packed days, we participated in a variety of workshops, shared our latest learnings and heard from our board members Jonathan Milner and our co-founder and chairman Dr. David Brown in a fireside chat. We're thankful for moments like these to collaborate under one roof, plan toward near-term goals, and celebrate our recent achievements together.
-
-
We're #hiring a new Business Development Senior Manager in Cambridge, England. Apply today or share this post with your network.
-
Our Chief Collaboration Officer Bruce Bloom participated in a round-table at the Global Genes 2024 RARE Advocacy Summit last week. Along with patient advocates and other industry peers, he discussed how drug developers can improve clinical trial feasibility through better engagement with #patientadvocacy organizations. Check out highlights from the event below!
-
-
October 1st is #CACNA1CAwareness Day, and we're joining Timothy Syndrome Alliance to help spread awareness for CACNA1C-related diseases and advocate for more research and treatment options for those affected by these diseases.
Today is #CACNA1C #AwarenessDay. Please show your support by sharing this post. We are hoping we can be loud all over the world. (This reel can be found in multiple languages on our YouTube account). CACNA1C-related disorders -> Are rare genetic disorders -> Affect an unknown number worldwide -> Can result in life-threatening health problems -> are often misdiagnosed -> currently have no cure TSA supports CACNA1C globally from the UK. We promote #research to understand how the gene changes cause symptoms and to develop therapies and treatments. CACNA1C-related disorders, including #TimothySyndrome and #LongQT8, are multisystemic and individuals found to have any CACNA1C gene change (including those with Variants of Uncertain Significance #VUS) should receive cardiac, developmental, psychiatric, endocrine (particularly diabetic) and neurological (epilepsy) screening. This however is currently not understood nor advocated for by key bodies including the National Health Service (NHS), something we are working on. For more information about our work please watch the latest film ‘Connections’ (found on our website, here and YouTube), a collaboration between the Timothy Syndrome Alliance (TSA) and Cardiff University / Prifysgol Caerdydd, we explore the importance of connections between individuals and families with lived experience of CACNA1C-related disorders (CRDs) and Timothy Syndrome (TS), academics, clinical teams and researchers. The more links we make, the stronger our network becomes and the faster we grow our understanding of our #raredisease. Without connections, we can't grow or learn. #RareDiseases #Awareness #calcium #ionchannels #channelopathies
-
Our Chief Collaboration Officer Bruce Bloom will be speaking at the Beacon for Rare Diseases Cambridge Rare Disease Showcase on 2nd October to discuss #AI development of #raredisease therapies. We're looking forward to sponsoring and speaking at this event which brings together industry experts, patient groups, and healthcare providers to share ideas, progress and achievements in rare diseases. Learn more about #RareShowcase24 here: https://lnkd.in/eHw5xhGd
-
-
At Healx, we are true believers that every rare disease patient deserves treatment. That's why our first company value is "care for rare". Every day, we strive to turn this value into action by leveraging cutting-edge #AI technology to accelerate the discovery of life-changing therapies for the #raredisease community. Dive into this company value below, and learn more about who we are here: https://healx.ai/about/